In early 2026, the diagnosis and staging of focal segmental glomerulosclerosis are being enhanced by artificial intelligence platforms that analyze kidney biopsies with 90% accuracy. These 2026 AI engines can identify subtle patterns of glomerular scarring and podocyte effacement that may be missed by traditional light microscopy alone. In early 2026, the use of urinary biomarkers like suPAR...